Articles from TRex Bio, Inc.

TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company discovering and developing precision immunoregulatory medicines based on tissue Treg biology, today announced the close of an oversubscribed $50 million financing. The financing included funding from new investors Janus Henderson Investors, Balyasny Asset Management L.P. and Affinity Asset Advisors, as well as existing investors Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc, Pfizer Ventures, Polaris Partners and SV Health Investors.

TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that members of its management team will participate in two upcoming investor conferences in September:

TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for TRB-061, a novel TNFR2 agonist initially being developed for the treatment of atopic dermatitis (AD).

TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the expansion of its executive leadership team with the appointments of Ariella Kelman, M.D., as Chief Medical Officer (CMO) and Brandon Hants, MBA, as Chief Financial Officer (CFO). These leadership additions will support TRexBio as the company prepares to initiate its first-in-human clinical trial of TRB-061, a novel TNFR2 agonist for the treatment of inflammatory diseases.

TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84 million Series B financing round. The financing was led by Delos Capital (“Delos”), with additional new investors Avego BioScience Capital (“Avego”) and Agent Capital. Existing investors Eli Lilly and Company (“Lilly”), SV Health Investors, Pfizer Ventures, Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.), Alexandria Venture Investments, and Polaris Partners also participated.

TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that collaboration partner Eli Lilly and Company (“Lilly”) has initiated a Phase 1 first-in-human study of TRB-051, a modulator of immune effector cells, for treatment of autoimmune and inflammatory diseases. The program is one of three under the research collaboration and exclusive worldwide license agreement between TRexBio and Lilly, which leverages TRexBio’s proprietary Deep Biology platform to identify and develop novel therapies for the treatment of immune-mediated diseases. Pursuant to the agreement, TRexBio has earned a double-digit million dollar milestone payment and is eligible to receive more than $1.1 billion on achievement of certain development, regulatory, and commercial milestones across partnered programs. TRexBio is also entitled to receive tiered royalties on product sales.

TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that Johnson & Johnson Innovative Medicine has exercised the first of its options for an exclusive license to develop and commercialize a program arising out of the parties’ collaboration. TRexBio announced the research collaboration focusing on the discovery of novel targets for immunology and inflammation in January 2022. In connection with the exercise of this option, TRexBio has earned a milestone payment and may be entitled to additional milestone and royalty payments as the program advances.

TRex Bio, Inc., (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the selection of development candidate TRB-061, an agonist targeting TNF receptor 2 (TNFR2). TRB-061 expands regulatory T cells (Tregs) to restore homeostasis in the tissue at the site of inflammation.

TRex Bio, Inc., (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to develop novel therapies for the treatment of immune-mediated diseases. This agreement builds on a previous collaboration with Lilly.